Download MendeleyDiscovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases.
Alper, P., Betschart, C., Andre, C., Boulay, T., Cheng, D., Deane, J., Faller, M., Feifel, R., Glatthar, R., Han, D., Hemmig, R., Jiang, T., Knoepfel, T., Maginnis, J., Mutnick, D., Pei, W., Ruzzante, G., Syka, P., Zhang, G., Zhang, Y., Zink, F., Zipfel, G., Hawtin, S., Junt, T., Michellys, P.Y.(2023) ACS Med Chem Lett 14: 1054-1062
- PubMed: 37583811
- DOI: https://doi.org/10.1021/acsmedchemlett.3c00136
- Primary Citation of Related Structures:
8PFI - PubMed Abstract:
Toll-like receptor (TLR) 7 and TLR8 are endosomal sensors of the innate immune system that are activated by GU-rich single stranded RNA (ssRNA). Multiple genetic and functional lines of evidence link chronic activation of TLR7/8 to the pathogenesis of systemic autoimmune diseases (sAID) such as Sjögren's syndrome (SjS) and systemic lupus erythematosus (SLE). This makes targeting TLR7/8-induced inflammation with small-molecule inhibitors an attractive approach for the treatment of patients suffering from systemic autoimmune diseases. Here, we describe how structure-based optimization of compound 2 resulted in the discovery of 34 (MHV370, ( S )-N-(4-((5-(1,6-dimethyl-1 H -pyrazolo[3,4- b ]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1 H -pyrazolo[4,3- c ]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide). Its in vivo activity allows for further profiling toward clinical trials in patients with autoimmune disorders, and a Phase 2 proof of concept study of MHV370 has been initiated, testing its safety and efficacy in patients with Sjögren's syndrome and mixed connective tissue disease.
Organizational Affiliation:
Novartis Institutes for Biomedical Research, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States.
